Intensive chemotherapy for childhood acute lymphoblastic leukemia: results of the randomized intercontinental trial ALL IC-BFM 2002

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
Jan StaryMartin Schrappe

Abstract

From 2002 to 2007, the International Berlin-Frankfurt-Münster Study Group conducted a prospective randomized clinical trial (ALL IC-BFM 2002) for the management of childhood acute lymphoblastic leukemia (ALL) in 15 countries on three continents. The aim of this trial was to explore the impact of differential delayed intensification (DI) on outcome in all risk groups. For this trial, 5,060 eligible patients were divided into three risk groups according to age, WBC, early treatment response, and unfavorable genetic aberrations. DI was randomized as follows: standard risk (SR), two 4-week intensive elements (protocol III) versus one 7-week protocol II; intermediate risk (IR), protocol III × 3 versus protocol II × 1; high risk (HR), protocol III × 3 versus either protocol II × 2 (Associazione Italiana Ematologia Oncologia Pediatrica [AIEOP] option), or 3 HR blocks plus single protocol II (Berlin-Frankfurt-Münster [BFM] option). At 5 years, the probabilities of event-free survival and survival were 74% (± 1%) and 82% (± 1%) for all 5,060 eligible patients, 81% and 90% for the SR (n = 1,564), 75% and 83% for the IR (n = 2,650), and 55% and 62% for the HR (n = 846) groups, respectively. No improvement was accomplished by more intense ...Continue Reading

References

Nov 1, 1983·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·J R AndersonR D Gelber
Jan 10, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Maurizio AricòValentino Conter
Mar 21, 2009·Pediatric Blood & Cancer·Tanya WattHoward M Katzenstein
Apr 4, 2009·Pediatric Blood & Cancer·Stephen M Shalet
Oct 7, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Kirk R SchultzBruce Camitta
Dec 18, 2009·Leukemia·J StaryUNKNOWN Czech Pediatric Hematology working group
Aug 13, 2010·British Journal of Haematology·Christine J HarrisonUNKNOWN Biology and Diagnosis Committee of International Berlin-Frankfürt-Münster study group
Sep 30, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Maurizio AricòMaria Grazia Valsecchi
Mar 14, 2012·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Stephen P HungerWilliam L Carroll
May 9, 2012·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Smita BhatiaF Lennie Wong

❮ Previous
Next ❯

Citations

Aug 12, 2014·Leukemia & Lymphoma·Hilda Verónica AráozMarisa Felice
Oct 24, 2015·Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases·Jan StyczynskiUNKNOWN Polish Society of Paediatric Oncology and Haematology
Oct 27, 2015·Journal of Cancer Research and Clinical Oncology·Huirong MaiFeiqiu Wen
May 23, 2015·Cancer Epidemiology·Florencia MorenoUNKNOWN ROHA network
Oct 16, 2015·The New England Journal of Medicine·Stephen P Hunger, Charles G Mullighan
Mar 27, 2015·Pediatric Blood & Cancer·Fang Fang ZhangMichael J Kelly
Sep 8, 2016·Clinical Lymphoma, Myeloma & Leukemia·José Carlos Jaime-PérezDavid Gómez-Almaguer
Oct 21, 2016·Leukemia & Lymphoma·Marcin BraunUNKNOWN Polish Pediatric Leukemia/Lymphoma Study Group
Dec 18, 2013·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Stephen P Hunger
Aug 26, 2015·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Ching-Hon PuiCharles G Mullighan
Jun 14, 2017·Expert Opinion on Pharmacotherapy·Raoul SantiagoHenrique Bittencourt
Mar 10, 2017·Pediatric and Developmental Pathology : the Official Journal of the Society for Pediatric Pathology and the Paediatric Pathology Society·Gheorghe PopaHoratiu Olteanu
Sep 15, 2017·European Journal of Haematology·Bronisława Szarzyńska-ZawadzkaMałgorzata Dawidowska
Apr 4, 2015·Future Oncology·Bhawna SirohiShailesh V Shrikhande
Apr 3, 2018·Journal of Pediatric Hematology/oncology·Li-Ping QueHai-Lei Chen
Jul 28, 2018·Pediatric Blood & Cancer·Alan Davidson, Scott C Howard
Nov 4, 2017·F1000Research·Jan Starý, Ondřej Hrušák
Jun 2, 2017·BMJ Case Reports·Siddhesh Arun KalantriMaitreyee Bhattyacharyya
Jul 18, 2018·Clinical Chemistry and Laboratory Medicine : CCLM·Margaritis AvgerisAndreas Scorilas
Nov 6, 2018·Journal of Cellular Biochemistry·Nashwa El-KhazragyRamez A Riad

❮ Previous
Next ❯

Related Concepts

Related Feeds

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

Related Papers

© 2021 Meta ULC. All rights reserved